Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Paolo Milani, MD PhD, Marco Basset, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1901.

https://doi.org/10.1182/blood-2019-130378

Published: 2019

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

Journal Articles

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Paolo Milani, MD, Marco Basset, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2018-99-118108

Published: 2018

Journal Articles

N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is an Independent Prognostic Factor for Overall Survival in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Paolo Milani, MD, Morie A. Gertz, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD, Martha Q Lacy, MD, Francis K Buadi, MD, Shaji K Kumar, MD, Suzanne R. Hayman, MD, Nelson Leung, MD, David Dingli, MD, John A. Lust, MD PhD, Yi Lin, MD PhD, Prashant Kapoor, MD, Ronald S. Go, MD, Yi L. Hwa, DNP, Steven Zeldenrust, MD, Robert A Kyle, MD, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2017) 130 (Supplement 1): 4349.

https://doi.org/10.1182/blood.V130.Suppl_1.4349.4349

Published: 2017

Journal Articles

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Esther Imperlini, PhD, Massimiliano Gnecchi, MD PhD, Paola Rognoni, PhD, Eduard Sabidò, PhD, Maria Chiara Ciuffreda, Giovanni Palladini, MDPhD, Guadalupe Espadas, Giuseppina Palladini, Stefania Orrù, PhD, Paolo Milani, MD PhD, Stefano Perlini, MD PhD, Francesco Salvatore, MD PhD, Giampaolo Merlini, MD, Francesca Lavatelli, MD PhD

Blood (2017) 130 (Supplement 1): 4393.

https://doi.org/10.1182/blood.V130.Suppl_1.4393.4393

Published: 2017

Journal Articles

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Giovanni Palladini, MDPhD, Ute Hegenbart, Paolo Milani, MD, Marco Basset, MD, Christoph Kimmich, MD, Francesca Russo, MD, Tilman Bochtler, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Stefan Schönland, MD

Blood (2017) 130 (Supplement 1): 1759.

https://doi.org/10.1182/blood.V130.Suppl_1.1759.1759

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

Journal Articles

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Giovanni Palladini, MDPhD, Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 4346.

https://doi.org/10.1182/blood.V130.Suppl_1.4346.4346

Published: 2017

Journal Articles

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

Giovanni Palladini, MD PhD, Margherita Massa, Marco Basset, MD, Francesca Russo, MD, Paolo Milani, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 3261.

https://doi.org/10.1182/blood.V128.22.3261.3261

Published: 2016

Journal Articles

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 2140.

https://doi.org/10.1182/blood.V128.22.2140.2140

Published: 2016

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Efstathios Kastritis, MD, Giampaolo Merlini, MD, Ioannis Papassotiriou, PhD, Paolo Milani, MD, Evangelos Terpos, Marco Basset, MD, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostoloakou, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Constantinos Pamboucas, Elektra Papadopoulou, Meletios A Dimopoulos, Giovanni Palladini, MD PhD

Blood (2016) 128 (22): 648.

https://doi.org/10.1182/blood.V128.22.648.648

Published: 2016

Journal Articles

Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients

Giovanni Palladini, MD PhD, Paolo Milani, MD, Eloisa Riva, MD, Marco Basset, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2015) 126 (23): 190.

https://doi.org/10.1182/blood.V126.23.190.190

Published: 2015

Journal Articles

N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)

Paolo Milani, MD, Morie A. Gertz, MD, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD, Martha Q. Lacy, MD, Francis K. Baudi, Shaji K. Kumar, MD, Suzanne R. Hayman, MD, Nelson Leung, MD, David Dingli, MD PhD, John A. Lust, MD PhD, Yi Lin, MD PhD, Prashant Kapoor, MD, Ronald S. Go, MD, Steven R. Zeldenrust, MD PhD, Yi L. Hwa, NP, Robert A. Kyle, MD, S. Vincent Rajkumar, Angela Dispenzieri, MD

Blood (2015) 126 (23): 3292.

https://doi.org/10.1182/blood.V126.23.3292.3292

Published: 2015

Journal Articles

In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)

Blood (2015) 126 (23): 1774.

https://doi.org/10.1182/blood.V126.23.1774.1774

Published: 2015

Journal Articles

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Paolo Milani, MD, Andrea Foli, MD, Marco Basset, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2015) 126 (23): 1773.

https://doi.org/10.1182/blood.V126.23.1773.1773

Published: 2015

Journal Articles

Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome

Giovanni Palladini, MD PhD, Paolo Milani, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2014) 124 (21): 3361.

https://doi.org/10.1182/blood.V124.21.3361.3361

Published: 2014

NARROW

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is an Independent Prognostic Factor for Overall Survival in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients

N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)

In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only